Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SYS003
MIFTS: 46

Systolic Heart Failure

Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Systolic Heart Failure

About this section

MalaCards integrated aliases for Systolic Heart Failure:

Name: Systolic Heart Failure 12 15
Heart Failure, Systolic 44 73

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9651
ICD10 33 I50.20
ICD9CM 35 428.2 428.20
MeSH 44 D054143
SNOMED-CT 68 417996009
UMLS 73 C1135191
Sources

Summaries for Systolic Heart Failure

About this section
MalaCards based summary : Systolic Heart Failure, also known as heart failure, systolic, is related to central sleep apnea and diastolic heart failure. An important gene associated with Systolic Heart Failure is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Folate Metabolism and Dilated cardiomyopathy (DCM). The drugs Furosemide and Verapamil have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Systolic Heart Failure

About this section

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 central sleep apnea 30.9 HSPB7 NPPB
2 diastolic heart failure 30.7 ACE NPPB
3 atrial fibrillation 30.3 ACE ADRB1 NPPB
4 apnea, obstructive sleep 30.3 CRP IL6 TNF
5 angina pectoris 30.1 ACE CRP IL6
6 intermittent claudication 30.1 ACE CRP IL6
7 arteries, anomalies of 29.7 ACE CRP IL6 NPPB TNF
8 sleep apnea 29.6 ACE CRP IL6 NPPB TNF
9 pulmonary disease, chronic obstructive 29.4 CRP IL6 NPPB TNF
10 chronic kidney failure 29.3 ACE CRP CST3 IL6 NPPB
11 kidney disease 29.2 ACE CRP CST3 NPPB NR3C2
12 peripheral artery disease 29.2 ACE CRP CST3 IL6
13 ischemic heart disease 29.2 ACE CRP IL6 NPPB TNF
14 diabetes mellitus, noninsulin-dependent 29.0 ACE CRP IL6 TNF
15 acute myocardial infarction 28.9 ACE ADRB1 CRP NPPB
16 congestive heart failure 28.8 ACE ADRB1 NPPB NR3C2
17 chagas disease 28.6 ACE ADRB1 IL6 NPPB TNF
18 coronary artery anomaly 27.9 ACE ADRB1 CRP CST3 IL6 NPPB
19 heart disease 26.3 ACE ADRB1 CRP CST3 IL6 NPPB
20 myocardial infarction 26.3 ACE ADRB1 CRP CST3 IL6 NPPB
21 dilated cardiomyopathy 25.4 ACE ADRB1 CRP HSPB7 IL6 LGALS3
22 peripartum cardiomyopathy 10.9
23 syndrome of inappropriate antidiuretic hormone 10.8 ACE NPPB
24 subacute cutaneous lupus erythematosus 10.7 ACE TNF
25 skin sarcoidosis 10.7 ACE TNF
26 aortic valve insufficiency 10.7 ACE NPPB
27 granulomatous dermatitis 10.7 ACE TNF
28 scorpion envenomation 10.7 IL6 TNF
29 leukomalacia 10.7 IL6 TNF
30 angioimmunoblastic lymphadenopathy with dysproteinemia 10.7 IL6 TNF
31 critical limb ischemia 10.7 IL6 TNF
32 streptococcal toxic-shock syndrome 10.7 IL6 TNF
33 null-cell leukemia 10.7 IL6 TNF
34 hand, foot and mouth disease 10.7 IL6 NPPB
35 retinitis pigmentosa 55 10.7 IL6 TNF
36 anca-associated vasculitis 10.7 IL6 TNF
37 chronic thromboembolic pulmonary hypertension 10.7 CRP NPPB
38 laryngitis 10.6 IL6 TNF
39 acute vascular insufficiency of intestine 10.6 IL6 TNF
40 generalized atherosclerosis 10.6 ACE CRP
41 poems syndrome 10.6 IL6 TNF
42 microscopic colitis 10.6 IL6 TNF
43 meconium aspiration syndrome 10.6 IL6 TNF
44 burning mouth syndrome 10.6 IL6 TNF
45 osteosclerotic myeloma 10.6 IL6 TNF
46 stachybotrys chartarum 10.6 IL6 TNF
47 anuria 10.6 ACE NR3C2
48 cold agglutinin disease 10.6 CRP IL6
49 renal hypertension 10.6 ACE NPPB
50 listeriosis 10.6 IL6 TNF

Graphical network of the top 20 diseases related to Systolic Heart Failure:



Diseases related to Systolic Heart Failure
Sources

Symptoms & Phenotypes for Systolic Heart Failure

About this section

MGI Mouse Phenotypes related to Systolic Heart Failure:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 IL6 LGALS3 NR3C2 TNF ACE ADRB1
2 homeostasis/metabolism MP:0005376 9.85 HSPB7 IL6 LGALS3 NR3C2 TNF ACE
3 muscle MP:0005369 9.5 CST3 HSPB7 IL6 NR3C2 TNF ADRB1
4 neoplasm MP:0002006 9.02 CST3 IL6 LGALS3 TNF ACE
Sources

Drugs & Therapeutics for Systolic Heart Failure

About this section

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
2
Verapamil Approved Phase 4 52-53-9 2520
3
Dobutamine Approved Phase 4 34368-04-2 36811
4
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
7
Ticlopidine Approved Phase 4 55142-85-3 5472
8
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
9
Metformin Approved Phase 4,Phase 2,Phase 1 657-24-9 14219 4091
10
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
11
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
12
Bisoprolol Approved Phase 4 66722-44-9 2405
13
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
14
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
15
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
16
Enalaprilat Approved Phase 4 76420-72-9 6917719
17
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Canagliflozin Approved Phase 4 842133-18-0
20
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
21
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
23 tannic acid Approved, Nutraceutical Phase 4
24 calcium channel blockers Phase 4
25 diuretics Phase 4,Phase 3
26
protease inhibitors Phase 4,Phase 2
27 Adrenergic Agents Phase 4,Phase 1,Not Applicable
28 Adrenergic Agonists Phase 4
29 Adrenergic alpha-1 Receptor Antagonists Phase 4
30 Adrenergic alpha-Antagonists Phase 4
31 Adrenergic Antagonists Phase 4,Not Applicable
32 Adrenergic beta-Agonists Phase 4
33 Adrenergic beta-Antagonists Phase 4,Phase 1,Not Applicable
34 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Sodium Potassium Chloride Symporter Inhibitors Phase 4
36 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
37 HIV Protease Inhibitors Phase 4,Phase 2
38 Nitric Oxide Donors Phase 4
39 Hormones Phase 4,Phase 3,Phase 1
40 Angiotensin Receptor Antagonists Phase 4
41 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 2
42 Anti-Arrhythmia Agents Phase 4,Not Applicable
43 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Not Applicable
45 Antihypertensive Agents Phase 4,Phase 2,Not Applicable
46 Protective Agents Phase 4
47 Autonomic Agents Phase 4,Not Applicable
48 Calcium, Dietary Phase 4,Phase 3
49 Atorvastatin Calcium Phase 4 134523-03-8
50 Prasugrel hydrochloride Phase 4 389574-19-0

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
2 Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Unknown status NCT00541268 Phase 4
3 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
4 Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
5 Danish ICD Study in Patients With Dilated Cardiomyopathy Unknown status NCT00542945 Phase 4
6 Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output (PRIORITY-ADHF Study) Unknown status NCT02767024 Phase 4 Sodium nitroprusside;Dobutamine;Furosemide
7 Platelet Inhibition in Patients With Systolic Heart Failure Completed NCT01765400 Phase 4 Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks
8 Medtronic South Asian Systolic Heart Failure Registry Completed NCT01434615 Phase 4
9 A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
10 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
11 Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure Completed NCT02401126 Phase 4
12 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
13 A Trial of Thiamin Supplementation in Patients With Heart Failure Completed NCT00959075 Phase 4
14 A Study Of The Usage Of Statins In A Community Heart Failure Population Completed NCT00795912 Phase 4 Atorvastatin
15 Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting Completed NCT02690974 Phase 4 LCZ696 (sacubitril/valsartan)
16 Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality Recruiting NCT03036462 Phase 4 Iron;Saline
17 Treatment of Diabetes in Patients With Systolic Heart Failure Recruiting NCT02920918 Phase 4 Canagliflozin;Sitagliptin
18 Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF) Recruiting NCT03096613 Phase 4 Levothyroxine
19 Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Recruiting NCT02768298 Phase 4 LCZ696;enalapril;Enalapril matching placebo;LCZ696 matching placebo
20 Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin Recruiting NCT03553303 Phase 4 Sacubitril / Valsartan Oral Tablet
21 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Recruiting NCT02579200 Phase 4
22 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
23 Metformin Pharmacokinetics in Patients With Chronic and Acute Heart Failure Active, not recruiting NCT02797340 Phase 4 Metformin
24 Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. Not yet recruiting NCT03392740 Phase 4 Lisinopril;Placebo Oral Tablet
25 Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST） Unknown status NCT02188082 Phase 2, Phase 3 IvabRadine hemisulfate Sustained-release Tablets;placebo
26 Imaging Study of Allocation of Pacing Targets in Cardiac Resynchronization Therapy Unknown status NCT01640769 Phase 3
27 Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction Unknown status NCT00497211 Phase 2, Phase 3
28 Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Completed NCT02998697 Phase 2, Phase 3 Ferrous Sulfate;Placebo Oral Capsule
29 Spinal Cord Stimulation For Heart Failure Completed NCT01362725 Phase 2, Phase 3
30 Crestor Versus Placebo in Subjects With Heart Failure Completed NCT00206310 Phase 3 CRESTOR
31 A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines Completed NCT00232180 Phase 3 Eplerenone
32 ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Completed NCT00111969 Phase 3
33 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD Completed NCT01754259 Phase 3 Ranolazine;Placebo
34 A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure. Completed NCT00270374 Phase 3 nesiritide
35 Cardiovascular Effects of Preferred Home-based Exercise Training in Systolic Heart Failure Recruiting NCT02051712 Phase 3
36 Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension Recruiting NCT01913847 Phase 3 Sildenafil;Placebo
37 Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients Recruiting NCT03388593 Phase 3 rhNRG-1;Placebo
38 Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
39 Renal Artery Denervation in Chronic Heart Failure Study Active, not recruiting NCT01639378 Phase 3
40 Blended Collaborative Care for Heart Failure and Co-Morbid Depression Active, not recruiting NCT02044211 Phase 2, Phase 3
41 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure Terminated NCT01646515 Phase 3 Placebo;Udenafil (Zydena)
42 Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients Terminated NCT01439893 Phase 3 rhNRG-1;Placebo
43 Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure Terminated NCT01214096 Phase 3 rhNRG-1;rhNRG-1;rhNRG-1;placebo
44 Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients Terminated NCT01541202 Phase 3 rhNRG-1;Placebo
45 Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients Terminated NCT01439789 Phase 3 rhNRG-1;Placebo
46 Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients Terminated NCT01131637 Phase 3 rhNRG-1;placebo
47 MADIT ASIA Cardiac Resynchronization Trial Terminated NCT01872234 Phase 3
48 Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure Completed NCT00923156 Phase 2 aliskiren;ramipril;Placebo to aliskiren;Placebo to ramipril
49 Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure Completed NCT01814319 Phase 2 Probenecid 1 gr oral twice daily;Placebo
50 A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure Completed NCT01096043 Phase 2 Placebo;Strata 1 CXL-1020;Strata 2 CXL-1020;Strata 3 CXL-1020

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Sources

Genetic Tests for Systolic Heart Failure

About this section
Sources

Anatomical Context for Systolic Heart Failure

About this section

MalaCards organs/tissues related to Systolic Heart Failure:

41
Heart, Testes, Brain, Kidney, Spinal Cord, Endothelial, Bone
Sources

Publications for Systolic Heart Failure

About this section

Articles related to Systolic Heart Failure:

(show top 50) (show all 672)
# Title Authors Year
1
Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine. ( 29896315 )
2018
2
Effect of Early Treatment With Ivabradine Plus Beta-blockers on Long-term Outcomes in Patients Hospitalized With Systolic Heart Failure. ( 29373253 )
2018
3
Acute Right Middle Cerebral Artery Occlusion Resulting in Acute Systolic Heart Failure, Cerebral T-Waves, and QTc Prolongation: A Case Report. ( 29953038 )
2018
4
Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. ( 29762337 )
2018
5
Systolic heart failure in a patient with primary aldosteronism. ( 29884668 )
2018
6
Utility of Left Atrial Expansion Index and Stroke Volume in Management of Chronic Systolic Heart Failure. ( 29426648 )
2018
7
Prediction of the ischemic origin of functional mitral regurgitation in patients with systolic heart failure through posterior mitral leaflet angle. ( 29942334 )
2018
8
Comparison of triple-site ventricular pacing versus conventional cardiac resynchronization therapy in patients with systolic heart failure: A meta-analysis of randomized and observational studies. ( 29721114 )
2018
9
Contractile reserve as a predictor of prognosis in patients with non-ischaemic systolic heart failure and dilated cardiomyopathy: a systematic review and meta-analysis. ( 29258998 )
2018
10
Resistance exercise enhances oxygen uptake without worsening cardiac function in patients with systolic heart failure: a systematic review and meta-analysis. ( 29199385 )
2018
11
Echocardiographic Insights into the Hemodynamics of Systolic Heart Failure: Can This Guide Titration of Medical Therapy? ( 29730184 )
2018
12
Dysregulations of miRNAs and galectin-3 may underlie left ventricular dilatation in patients with systolic heart failure. ( 29905365 )
2018
13
Three-dimensional echocardiographic evaluation of mechanical dyssynchrony in systolic heart failure with narrow QRS complex. ( 29961455 )
2018
14
Is There a Sex-Related Difference in the Obesity Paradox in Systolic Heart Failure? Sex-Related Difference in the Obesity Paradox. ( 29214777 )
2018
15
The interaction of QRS duration with cardiac magnetic resonance derived scar and mechanical dyssynchrony in systolic heart failure: Implications for cardiac resynchronization therapy. ( 29750182 )
2018
16
Pulmonary hypertension due to left heart disease: diagnostic and prognostic value of CT in chronic systolic heart failure. ( 29761362 )
2018
17
Hopelessness and cognitive impairment are risk markers for mortality in systolic heart failure patients. ( 29773147 )
2018
18
Has the Time Come to Be More Aggressive With Bariatric Surgery in Obese Patients With Chronic Systolic Heart Failure? ( 29629485 )
2018
19
Accuracy of cardiac magnetic resonance imaging to rule out significant coronary artery disease in patients with systolic heart failure of unknown aetiology: Single-centre experience and comprehensive meta-analysis. ( 29861294 )
2018
20
Systolic heart failure after liver transplantation: Incidence, predictors, and outcome. ( 29323769 )
2018
21
Daily non-invasive haemodynamic telemonitoring for efficacy evaluation of MitraClipAr implantation in patients with advanced systolic heart failure. ( 29893475 )
2018
22
Percutaneous renal artery denervation in patients with chronic systolic heart failure: a randomized controlled trial. ( 29611171 )
2018
23
Neopterin as a novel marker; well correlated with mortality and morbidity in patients with advanced systolic heart failure. ( 29914304 )
2018
24
The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study. ( 27865188 )
2017
25
Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. ( 28068900 )
2017
26
Acute Effects of Positive Airway Pressure on Functional Mitral Regurgitation in Patients with Systolic Heart Failure. ( 29218014 )
2017
27
Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure. ( 27979033 )
2017
28
Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure. ( 29154425 )
2017
29
Prognostic impact of diastolic dysfunction in systolic heart failure-A cross-project analysis from the German Competence Network Heart Failure. ( 28467622 )
2017
30
Mobitz Type II Atrioventricular Block following Tramadol and Fentanyl in a Patient with Acute Coronary Syndrome and Systolic Heart Failure. ( 29184615 )
2017
31
Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). ( 29141858 )
2017
32
Global longitudinal strain corrected by RR interval is a superior predictor of all-cause mortality in patients with systolic heart failure and atrial fibrillation. ( 29024533 )
2017
33
Basic research: Inhibition of Hippo pathway signalling reverses systolic heart failure. ( 29053154 )
2017
34
C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty. ( 28883850 )
2017
35
Age and Outcomes of Primary Prevention Implantable Cardioverter Defibrillators in Patients with Non-Ischemic Systolic Heart Failure. ( 28877914 )
2017
36
Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management. ( 28523441 )
2017
37
Adherence to systolic heart failure guidelines in ambulatory care in Poland - data from the international QUALIFY survey. ( 28786405 )
2017
38
Ivabradine - well tolerated in elderly patients with systolic heart failure. ( 29121737 )
2017
39
Dissociation of Objective and Subjective Daytime Sleepiness and Biomarkers of Systemic Inflammation in Sleep-Disordered Breathing and Systolic Heart Failure. ( 29065958 )
2017
40
Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease. ( 28709768 )
2017
41
Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). ( 27884420 )
2017
42
Severely Impaired Cardiorespiratory Fitness in Patients With Recently Decompensated Systolic Heart Failure. ( 28867128 )
2017
43
Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF. ( 29193576 )
2017
44
Prevalence of airflow obstruction in patients with stable systolic heart failure. ( 28061834 )
2017
45
Determinants of improvement in six-minute walk distance from admission to discharge in acute systolic heart failure: Analysis from the ESCAPE trial. ( 28421593 )
2017
46
Adaptive Servo-Ventilation Treatment Increases Stroke Volume in Stable Systolic Heart Failure Patients With Low Tricuspid Annular Plane Systolic Excursion. ( 28484123 )
2017
47
The Impact of Bronchodilator Therapy on Systolic Heart Failure with Concomitant Mild to Moderate COPD. ( 29283405 )
2017
48
Improvement of exercise tolerance in cardiopulmonary testing with sustained safety after regular training in outpatients with systolic heart failure (NYHA III) and an implantable cardioverter-defibrillator. Prospective 18-month randomized study. ( 28883851 )
2017
49
Mortality prediction using CHADS2/CHA2DS2-VASc/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation. ( 29069008 )
2017
50
Anxiety and self-care behaviour in patients with chronic systolic heart failure: A multivariate model. ( 28718661 )
2017
Sources

Variations for Systolic Heart Failure

About this section
Sources

Expression for Systolic Heart Failure

About this section
Search GEO for disease gene expression data for Systolic Heart Failure.
Sources

Pathways for Systolic Heart Failure

About this section

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Folate Metabolism 1
Show member pathways
 11.97 CRP IL6 TNF
2
Dilated cardiomyopathy (DCM) 37
Show member pathways
 11.49 ACE ADRB1 IL6 TNF
3
Spinal Cord Injury 1
11.41 IL6 LGALS3 TNF
4
Development and heterogeneity of the ILC family 1
10.94 IL6 TNF
5
Antifolate resistance 37
10.9 IL6 TNF
6
Cytokines and Inflammatory Response 1
10.85 IL6 TNF
7
A-beta Pathways: Plaque Formation and APP Metabolism 65
10.68 ACE CST3
8
Transcription factor regulation in adipogenesis 1
10.6 IL6 TNF
9
Overview of nanoparticle effects 1
10.08 CRP IL6 TNF
Sources

GO Terms for Systolic Heart Failure

About this section

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ACE CRP CST3 IL6 LGALS3 NPPB
2 extracellular region GO:0005576 9.23 ACE CORIN CRP CST3 IL6 LGALS3

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 9.5 CRP IL6 TNF
2 positive regulation of chemokine production GO:0032722 9.4 IL6 TNF
3 regulation of blood vessel diameter GO:0097746 9.37 ACE NPPB
4 regulation of blood pressure GO:0008217 9.33 ACE CORIN NPPB
5 neutrophil mediated immunity GO:0002446 9.26 ACE IL6
6 positive regulation of mononuclear cell migration GO:0071677 8.96 LGALS3 TNF
7 negative regulation of lipid storage GO:0010888 8.8 CRP IL6 TNF
Sources

Sources for Systolic Heart Failure

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....